Clinical Trials Logo

Clinical Trial Summary

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.


Clinical Trial Description

This randomized, double-blinded, placebo-controlled Phase 3 study will examine the immune response and the safety and tolerability profiles across 3 manufactured lots of RSVpreF when administered as a single 120 µg dose to healthy adults to demonstrate lot equivalence in manufacturing of RSVpreF. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05096208
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 3
Start date October 21, 2021
Completion date April 4, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06160128 - COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System
Completed NCT05585632 - A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old Phase 1
Completed NCT05778240 - Adherence to Palivizumab Prophylaxis N/A
Recruiting NCT01985620 - The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate. N/A